Deals > All

Eastern Europe Northern Europe Southern Europe Western Europe

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 9697 | Ordered by Date (descending)
1 2 3 ... 95 96 97

Deal: Collaboration or Financing	Date
Merck (DE)–Caris Life Sciences: AI-based drug discovery, 202404– collab strategic up to $1.4b discovery of cancer targets for ADC RnD	2024-04-04
ProfoundBio–Genmab: investment, 202403– acqusition $1.8b in cash of ProfoundBio by Genmab ANNOUNCED	2024-04-03
SurgeCare–50 Partners Santé: investment, 202403 2nd financing round totalling €7.5m incl existing + co-investor 50 Partners Santé	2024-03-27
SurgeCare–Boutique Venture: investment, 202403 2nd financing round totalling €7.5m incl existing + co-investor Boutique Venture	2024-03-27
SurgeCare–Eurazeo: investment, 202403 2nd financing round totalling €7.5m incl lead investor Eurazeo	2024-03-27
SurgeCare–France (govt): grant, 202403c BPI grants incl support for deep tech development + Future Investment Program	2024-03-27
SurgeCare–HCVC: investment, 202403 2nd financing round totalling €7.5m incl existing + co-investor HCVC	2024-03-27
SurgeCare–Kima: investment, 202403 2nd financing round totalling €7.5m incl co-investor Kima	2024-03-27
SurgeCare–MH Innov’: investment, 202403 2nd financing round totalling €7.5m incl co-investor MH Innov’	2024-03-27
SurgeCare–SEVERAL: investment, 202403 2nd financing round €7.5m led by Eurazeo	2024-03-27
SurgeCare–Teampact Ventures: investment, 202403 2nd financing round totalling €7.5m incl co-investor Teampact	2024-03-27
Innocent Meat–Mecklenburg-Vorpommern (govt): investment, 202403 financing round totalling €3m incl €500k from existing investor VC Fonds MV	2024-03-26
Innocent Meat–OTHER: investment, 202403 financing round totalling €3m incl €2.5m from a new private investor	2024-03-26
Innocent Meat–SEVERAL: investment, 202403 financing round €3m with Venture Capital Fonds MV + new private investor	2024-03-26
Protembis–SEVERAL: investment, –202403 financing round Series B €30m completed in two separate capital increases	2024-03-26
Cardior Pharmaceuticals–Novo Group: investment, 202403– acquisition for up to €1.025b incl upfront payment + milestones ANNOUNCED	2024-03-25
Hemotune–SEVERAL: investment, 202403 financing round Series B2 CHF14m led by Belmondo	2024-03-25
Kranus Health–Anaxago: investment, 202403 financing round Series A expansion totalling $5m incl new investor CapHorn	2024-03-25
Kranus Health–Future Positive Capital: investment, 202403 financing round Series A expansion totalling $5m incl new investor Future Positive Capital	2024-03-25
Kranus Health–SEVERAL: investment, 202403 financing round Series A expansion $5m bringing total Series A to $20m	2024-03-25
Volumina Medical–SEVERAL: investment, 202403 financing round Series A $21m with existing + new investors	2024-03-25
Avation Medical–Angelini: investment, 202403 existent investment of Angelini Ventures	2024-03-21
Cadence Neuroscience–Angelini: investment, 202403 existent investment of Angelini Ventures	2024-03-21
Cour Pharmaceuticals–Angelini: investment, 202403 existent investment of Angelini Ventures	2024-03-21
Mirador Therapeutics–Sanofi: investment, 202403 Mirador emerges with total of >$400m in financing incl investor Sanofi Ventures	2024-03-21
Mirador Therapeutics–SEVERAL: investment, 202403 emerges with >$400m in financing led by ARCH Venture with early investments by OrbiMed + Fairmount	2024-03-21
Noctrix Health–Angelini: investment, 202403 existent investment of Angelini Ventures	2024-03-21
Nouscom–Angelini: investment, 202403 investment €7m from Angelini Ventures as Series C extension bringing total round to €75.8m	2024-03-21
Sanofi–Owkin: AI-based drug development, 202403– collab expansion into using AI for drug positioning in immunology	2024-03-21
Capstan Therapeutics–Bayer: investment, 202403 financing round Series B totalling $175m incl existing + co-investor Leaps by Bayer	2024-03-20
Capstan Therapeutics–Forbion: investment, 202403 financing round Series B totalling $175m incl new + co-investor Forbion	2024-03-20
Capstan Therapeutics–Novartis: investment, 202403 financing round Series B totalling $175m incl existing + co-investor Novartis Venture Fund	2024-03-20
Capstan Therapeutics–SEVERAL: investment, 202403 financing round Series B $175m led by RA Capital Management	2024-03-20
Cure51–Hitachi: investment, 202403 seed financing round totalling €15m incl co-investor Hitachi Ventures GmbH	2024-03-20
Cure51–Life Extension Ventures: investment, 202403 seed financing round totalling €15m incl co-investor Life Extension Ventures	2024-03-20
Cure51–PERSON: investment, 202403 seed financing round totalling €15m incl co-investors Xavier Niel + Olivier Pomel	2024-03-20
Cure51–SEVERAL: investment, 202403 seed financing round €15m led by Sofinnova Partners	2024-03-20
Cure51–Sofinnova: investment, 202403 seed financing round totalling €15m incl lead investor Sofinnova Partners	2024-03-20
Roche–Lonza: investment, 202403– acquisition $1.2b in cash of Genentech biologics manufacturing facility in California from Roche	2024-03-20
Engrail Therapeutics–abrdn: investment, 202403 financing round Series B totalling $157m incl co-investor funds managed by abrdn Inc	2024-03-19
Engrail Therapeutics–F-Prime: investment, 202403 financing round Series B totalling $157m incl new + co-lead investor F-Prime Capital	2024-03-19
Engrail Therapeutics–Forbion: investment, 202403 financing round Series B totalling $157m incl new + co-lead investor Forbion	2024-03-19
Engrail Therapeutics–SEVERAL: investment, 202403 financing round Series B $157m led by F-Prime + Forbion + Norwest	2024-03-19
Engrail Therapeutics–Ysios Capital: investment, 202403 financing round Series B totalling $157m incl co-investor Ysios Capital	2024-03-19
Ceban Pharmaceuticals–Medios: investment, 202403– acquisition 100% of Ceban for €235.3m cash + €23.9m in shares from funds managed by Bencis	2024-03-18
Alithea Genomics–Novalis Biotech: investment, 202303 seed financing round extension totalling CHF2.8m incl existing + lead investor Novalis Biotech AF	2024-03-14
Alithea Genomics–SEVERAL: investment, 202303 seed financing round extension CHF2.8m led by Novalis Biotech Acceleration Fund	2024-03-14
Alithea Genomics–TechU Ventures: investment, 202303 seed financing round extension totalling CHF2.8m incl new + co-investor TechU Ventures	2024-03-14
Amolyt Pharma–AstraZeneca: investment, 202403– acquisition $800m upfront cash + $250m milestones	2024-03-14
Nuclera–Zyme Communications: public relations, 202403 service existent by Zyme	2024-03-14
Tubulis–Andera Partners: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Andera Partners	2024-03-14
Tubulis–Bavaria (govt): investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor ScaleUp-Fonds Bayern	2024-03-14
Tubulis–BioMedPartners: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor BioMedPartners	2024-03-14
Tubulis–BPCE: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Seventure Partners	2024-03-14
Tubulis–Deep Track Capital: investment, 202403 financing round Series B2 totalling €128m incl new + co-investor Deep Track Capital	2024-03-14
Tubulis–EQT: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor EQT Life Sciences	2024-03-14
Tubulis–Evotec: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Evotec	2024-03-14
Tubulis–Frazier: investment, 202403 financing round Series B2 totalling €128m incl new + co-investor Frazier Life Sciences	2024-03-14
Tubulis–Fund+: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Fund+	2024-03-14
Tubulis–Germany (govt): investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Coparion	2024-03-14
Tubulis–High-Tech Gründerfonds: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor HTGF	2024-03-14
Tubulis–Nextech: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor Nextech Invest Ltd	2024-03-14
Tubulis–Occident: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Occident	2024-03-14
Tubulis–SEVERAL: investment, 202403 financing round Series B2 €128m led by EQT Life Sciences + Nextech Invest	2024-03-14
Mapp Biopharmaceutical–Minapharm: cell line development, 202403– supply service + license €na ProBioGen using GlymaxX for production of MBP091	2024-03-13
Ricoh–ERS Genomics: CRISPR technology, 202001– license non-excl in US + Japan to Ricoh Company	2024-03-13
HiDocTechnologies–Mahana Therapeutics: investment, 202403 acquisition €na of Cara Care by Mahana Therapeutics	2024-03-12
Boehringer–Sosei: GPR52 agonists, 202403– collab drug discovery + excl ww license option €25m upfront + €730m milestones plus tiered royalties	2024-03-11
NanoString–Patient Square Capital: investment, 202403– acquisition $220m of substantially all assets as going concern under Bankruptcy Code	2024-03-10
ProteinDistillery–SEVERAL: investment, 202403 seed financing round €15m (incl credits/grants?) led by Green Generation Fund + Startup Family Office	2024-03-07
Merck (DE)–C4 Therapeutics: protein degraders, 202403– license + collab $16m upfront + $740m milestones + royalties discovery of 2 protein degraders	2024-03-04
BRAIN Biotech–Putsch (Recaro): credit, 202402–202609 convertible bond €5m with MP Beteiligungs-GmbH at 6.52% p.a.	2024-02-29
Inpart–Norstella: business services, 202409– collab integrating Evaluate data into Deal CRM of Inpart	2024-02-29
Neobe Therapeutics–SEVERAL: Investment, 202402 financing round $2.34m led by Pioneer Group incl grant from Innovate UK	2024-02-29
Stilla Technologies–SEVERAL: investment, 202402 financing round Series C $26.5m led by CLIIF	2024-02-22
Cresset–Enamine: virtual drug screening, 202402– collab ww applying Ignite virtual screening technology to Enamine REAL Space library	2024-02-21
Cyclize–Aurum Impact: investment, 202402 seed financing round totalling €4.75m incl co-investor Aurum Impact	2024-02-21
Cyclize–High-Tech Gründerfonds: investment, 202402 seed financing round totalling €4.75m incl co-investor HTGF	2024-02-21
Cyclize–OTHER: investment, 202402 seed financing round totalling €4.75m incl high-profile business angels	2024-02-21
Cyclize–PERSON: investment, 202402 seed financing round totalling €4.75m incl business angel Klaus Schäfer	2024-02-21
Cyclize–SEVERAL: investment, 202402 seed financing round €4.75m led by UVC Partners	2024-02-21
Cyclize–TU Munich: investment, 202402 seed financing round totalling €4.75m incl co-investor UnternehmerTUM Funding for Innovators	2024-02-21
Cyclize–UVC Partners: investment, 202402 seed financing round totalling €4.75m incl lead investor UVC Partners	2024-02-21
Waters–Plasmion: ionisation technology, 202402– collab co-marketing/promotion of SICRIT ion source with Waters Acquity QDa + Select Series Cycli IMS	2024-02-21
AZmed–Maison Worms: investment, 202402 financing round Series A totalling €15m incl investor Maison Worms	2024-02-20
AZmed–SEVERAL: investment, 202402 financing round Series A €15m	2024-02-20
AZmed–Teampact Ventures: investment, 202402 financing round Series A totalling €15m incl investor Teampact Ventures	2024-02-20
AZmed–Techstars: investment, 202402 financing round Series A totalling €15m incl investor Techstars	2024-02-20
Bioptimus–SEVERAL: investment, 202402 company emerges with seed financing round $35m led by Sofinnova Partners	2024-02-20
GlycanAge–SEVERAL: investment, 202402 seed financing round €3.9m led by LauncHub Ventures + Kadmos Capital	2024-02-19
MIP Discovery–Calculus Capital: investment, 202402 financing round Series A totalling £7m incl exsiting + co- investor Calculus Capital	2024-02-19
MIP Discovery–Mercia: investment, 202402 financing round Series A totalling £7m incl lead investor Mercia Ventures	2024-02-19
MIP Discovery–OTHER: investment, 202402 financing round Series A totalling £7m incl angel investors	2024-02-19
MIP Discovery–SEVERAL: investment, 202402 financing round Series A £7m led by Mercia Ventures	2024-02-19
Firefly Bio–SEVERAL: investment, 202402c emerges with financing round Series A $94m co-led by Versant Ventures + MPM BioImpact	2024-02-15
Firefly Bio–Versant Ventures: investment, 202402c emerges with financing round Series A totalling $94m incl co-lead investor Versant Venture	2024-02-15
Freenome–Roche: investment, 202402 financing round totalling $254m incl existing + lead investor Roche	2024-02-15
Freenome–SEVERAL: investment, 202402 financing round $254m led by Roche	2024-02-15
Sysmex–SAFIA Technologies: mycotoxin immunoassays, 202402– distribution ww of tests for food/agri by Sysmex Partec using SAFIA tech + flow cytometry	2024-02-15
Earlybird–Barmer: investment, 202402 final closing of new Earlybird Health Fund totalling €173m incl investor Barmer	2024-02-14

1 2 3 ... 95 96 97

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]